

A Study on the Impact of Artificial Intelligence in Pharmaceuticals

Vedant V. Patil^{1,*}, Roshan M. Chaudhari², S.P. Pawar³

Abstract

The main goal of artificial intelligence (AI) is to create intelligent modeling, which facilitates knowledge imagination, problem-solving, and decision-making. AI is becoming more and more significant in several pharmacy domains, including polypharmacology, hospital pharmacy, drug discovery, and drug delivery formulation development. Various types of artificial neural networks (ANNs), including deep neural networks (DNNs) and recurrent neural networks (RNNs), are utilized in the development of drug delivery formulations and in drug discovery. The technology's promise in quantitative structure-property relationships (QSPR) and quantitative structure-activity relationships (QSAR) has been supported by several drug discovery implementations that have been studied thus far. In terms of desired/optimal properties, de novo design also promotes the creation of significantly more innovative medical substances. This review paper discusses the application of AI in pharmacy, specifically in areas, such as polypharmacology, the development of drug delivery formulations, drug discovery, and hospital pharmacy. A branch of computer science called artificial intelligence makes it possible for machines to function efficiently. Because of its capacity to manage complex data processing tasks, which has enhanced workflow efficiency, its use in pharmaceutical technology has expanded. Reducing operating expenses while enhancing safety, precision, and efficiency. It might help us conserve time and resources while enhancing our comprehension of the relationships among different formulations and process parameters. Research in artificial intelligence (AI) has surged, and it has been shown that AI technology can analyze and understand data across several key areas in pharmacy, including hospital pharmacy, formulation design, and drug discovery.

Keywords: Artificial intelligence, drug discovery, drug delivery research, hospital pharmacy, telepsychology, MEDi robot

INTRODUCTION

The examination of smart machine learning, mainly via intelligent software that generates results like human focus, is referred to as artificial intelligence (AI) [1]. This procedure usually consists of

*Author for Correspondence

Vedant V. Patil

E-mail: vedantp381@gmail.com

¹Student, Department of Pharmaceutics, Poojya Sane Guruji Vidya Prasarak Mandal, Shahada, Maharashtra, India

²Assistant Professor, Department of Pharmaceutics, Poojya Sane Guruji Vidya Prasarak Mandal, Shahada, Maharashtra, India

³Principal, Department of Pharmaceutics, Poojya Sane Guruji Vidya Prasarak Mandal, Shahada, Maharashtra, India

Received Date: November 23, 2024

Accepted Date: January 16, 2025

Published Date: January 20, 2025

Citation: Vedant V. Patil, Roshan M. Chaudhari, S.P. Pawar. A Study on the Impact of Artificial Intelligence in Pharmaceuticals. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(1): 24–32p.

collecting data, developing efficient methods for utilizing the data, displaying accurate or approximate findings, and adjusting and self-corrections [2]. Artificial intelligence (AI) is frequently employed to simulate human cognitive activities and examine machine learning. The application of AI technology results in more accurate assessments and practical interpretation. According to this viewpoint, computational intelligence and several practical statistical models are integrated into AI technology. The worry of the prospect of unemployment is often linked to the advancement and invention of AI applications. But nearly every breakthrough in the use of AI technology is being praised because of the industry's confidence, which greatly increases the

technology's effectiveness. AI technology has grown significantly in importance recently because of its practical applications in a wide range of technological and scientific domains [3, 4]. The excitement around AI technology in pharmacy, encompassing drug discovery, drug delivery formulation creation, and other healthcare uses, has already led to optimism due to the growing initiatives to recognize its benefits [5, 6].

AI models also enable the prediction of in vivo reactions, therapeutic pharmacokinetics, appropriate dosages, and various other elements [7]. Given the significance of drug pharmacokinetic prediction, the use of in silico models in drug development contributes to its affordability and efficacy [8].

The advancements in AI technology fall into two main categories. Expert systems, which may mimic human experiences and provide judgments, are among the traditional computer approaches included in the first one. the fundamentals, such as expert systems. The second one consists of artificial neural network (ANN)-based technologies that can simulate how the brain functions [9]. Specifically, the advancement of AI technology is governed by several artificial neural networks (ANNs), such as deep neural networks (DNNs) and recurrent neural networks (RNNs). The challenges associated with DNN also extend to de novo design, which encourages the creation of novel pharmacological compounds based on optimal or preferred characteristics [10].

This review article examines the application of AI in pharmacy, specifically in drug discovery, formulation development for drug delivery, polypharmacology, and hospital pharmacy. The outcomes of the Merck Kaggle and NIH Tox21 challenge demonstrate superior predictability compared to the standard machine learning techniques [11–13]. Suitable statistical techniques are employed in machine learning, allowing it to learn either with or without direct coding. Moreover, de novo design fosters the creation of novel therapeutic agents concerning optimal or preferred characteristics [14]. The present review article examines the application of AI in pharmacy, particularly in polypharmacology, hospital pharmacy, drug delivery formulation development, and drug discovery.

The field of computer science referred to as artificial intelligence (AI) develops machines capable of mimicking human intelligence and executing tasks that typically require human-like reasoning. These duties entail learning, decision-making, and problem-solving. The pharmaceutical industry uses artificial intelligence (AI) to forecast outcomes, diagnose patterns, and analyze vast amounts of data. This results in faster and more accurate conclusions [15].

Currently, artificial intelligence plays a crucial role in pharmaceutical research, particularly in the development of new medications. Artificial intelligence (AI) has revolutionized the drug development process by creating smart machines capable of executing tasks that necessitate human-like intelligence. This method used to be expensive and time-consuming. These responsibilities include problem-solving, decision-making, and learning. AI is used in the pharmaceutical sector to uncover possible medication candidates by analyzing large datasets, finding trends, and screening millions of molecules. This process produces data-driven results more quickly and accurately [16]. AI is also capable of optimizing medication creation through the analysis and prediction of compounds' attributes based on their chemical structure. By identifying possible changes to increase their safety and efficacy, this can significantly cut down on the time and expense involved with using conventional drug design techniques [17].

Furthermore, AI is essential to clinical studies. Patient recruitment for clinical studies may be difficult and time-consuming. However, potential patients can be identified by AI algorithms based on their medical history and other factors, speeding up and improving the effectiveness of the recruiting process [18].

Milestones in AI

The phrase "Artificial intelligence" was first used in 1956. However, the concept of artificial intelligence has been applied since 1950 in combination with problem-solving methods and symbolic approaches. Table 1 enumerates five pivotal moments in the history of AI applications.

Table 1. Important milestones in the area of the AI uses.

Year	Events
1943	It was demonstrated by Walter Pitts and Warren McCulloch that neurons coupled in a network may perform logical operations like “and,” “or,” and “not.”
1956	The word “artificial intelligence” was first developed.
1958	Perceptrons are neural networks developed by Frank Rosenblatt that have one-way information transmission capabilities.
1974	The “First AI Winter” gets started.
1986	The backpropagation algorithm, which is frequently used in deep learning, was introduced by Geoffrey Hinton.
1987	“AI winter” really started.
1997	IBM Deep Blue won successfully against Russian grandmaster Garry Kasparov.
2013	Google used British technology to efficiently conduct research on images.
2016	This year, Google DeepMind’s AlphaGo AI beat Go Champion Lee Sedol.




Figure 1. Classification of AI.

Classification of AI

- AI may be categorized in two distinct ways: by existence and by caliber (Figure 1). AI may be divided into the following groups based on its capabilities:
 - Artificial Narrow Intelligence (ANI)*, also known as *Weak AI*: It can perform a limited range of tasks, such as facial recognition, driving, practicing chess, and managing traffic lights.
 - Artificial General Intelligence (AGI)*, also known as *strong AI*, is a form of AI that can perform at a level comparable to humans. It can streamline human intelligence and execute tasks that exceeds its abilities.
 - Artificial Super Intelligence (ASI)*: In areas, such as mathematics, drawing, space exploration, and more, it is considerably more dynamic and intelligent than people [19, 20].

The subsequent categories can be utilized to categorize AI according to their current usage status.

1. *Type 1*: An AI system of this kind is referred to as a reactive machine. For instance, the IBM chess computer Deep Blue defeated Garry Kasparov in the 1990s. It lacks the memory to draw on earlier experiences, yet it can detect checkers on a chessboard and make predictions. It is useless in other circumstances and was made with certain uses in mind.

AlphaGo from Google is another example.

2. *Type 2*: This type of AI system is known as a restricted memory system. This strategy might apply historical insights to present and future problems. The creation of different autonomous car decision-making functions only employs this tactic. The acts that take place in the future, such a car changing lanes, are documented using the observed data. The observations are not retained in the mind indefinitely.
3. *Type 3*: AI systems of this type are referred to as “theory of mind” systems. It implies that every person has thoughts, goals, and wants that influence the choices they make. This AI doesn’t exist.
4. *Type 4*: These are said to as self-aware. Artificial intelligence (AI) systems are sentient and possess a sense of self; if the computer is self-aware, it recognizes the circumstances and utilizes the ideas that are present in other people’s minds [21].

AI’s Goals

1. *Establishing an expert*: Systems entails constructing intelligent, automated systems that can give advice to people regarding the optimal course of action.
2. *Human Intelligence in Computers*: As a result, computers will pick up cognitive functions that are comparable to those of people, enabling them to act like people and make intelligent decisions in challenging circumstances. This will reduce the amount of work that has to be done by humans utilizing algorithms and enable automated operations.
3. *Multi-Domain Use*: AI will be used in a variety of fields, including computer science, cognitive science, statistics, psychology, engineering, ethics, healthcare, the natural sciences, space technology, logic, languages, and more.
4. *Applications in Computer Science*: A wide range of methods that tackle several challenging issues in the field of computer science are developed using artificial intelligence (AI). Logic, control theory, language analysis, neural networks, classifiers, search and optimization, statistical learning techniques, and probabilistic methods for uncertain reasoning are among these procedures [22].

Artificial Intelligence in Telepsychology [E-Therapy]

Artificial intelligence could be able to derive a significant association from raw datasheets. This also applies to the diagnosis, treatment plan, and mitigation of the illness.

Several of the more modern techniques used in this developing discipline of computational understanding might find use in almost every area of medical research. The difficulty of acquiring, evaluating, and utilizing an abundance of information needs to be surmounted to address the challenging clinical issues. The progress of AI in healthcare has helped professionals tackle difficult clinical problems.

Systems, such as uncertain expert systems, hybrid intelligence systems, evolutionary computational models, and artificial neural networks (ANNs) can be used to manipulate data for healthcare workers. The ANN is modeled after the organic nervous system and uses a network of interconnected computer processors that resemble neurons to process data concurrently. The first artificial neuron used a binary threshold function. A well-known model was the multilayer feed-forward perceptron, which has separate layers for the input, middle, and output layers. Connectivity between each neuron is established using numerical weights (Figure 2) [23].

Artificial Intelligence in Radioecology

A new technical development in radiation therapy treatment planning is automated treatment planning, which has several benefits. It lowers mistake rates and successfully improves plan quality and consistency. Modeling of prior clinical information, multi-criteria optimization, and automated rule application are the three components of the therapy process. Clinical recommendations are easily implemented using a simple computer application that follows pre-established patterns. The system for treatment planning can analyze the anatomy and physiology of a patient and simulating the cognitive process that is commonly employed in treatment planning by hand. Radiomics can be used to evaluate toxicity and forecast treatment results for specific radiation therapy patients [24].



Figure 2. Artificial intelligence in telepsychology.

Artificial Intelligence in Ophthalmology

Excellent progress has been achieved in evaluating human health thanks to retinal high-resolution imaging. An ophthalmologist or retina specialist can create a personalized treatment plan and implement a continuously improving learning healthcare system using just one retinal image and high-definition medication [25].

Artificial Intelligence in Oncology

Because AI has so many uses, it has grown in significance in the disciplines of cancer detection and therapy. A multilayer perceptron neural network was trained to forecast the subtypes of non-Hodgkin lymphoma using gene expression data (Figure 3) [26].

The input region of the network of neurons consists of 20, 863 genes, while the result layer is composed of cancer subtypes. The subtypes of cancer include Burkitt, mantle cell lymphoma (MCL), follicular lymphoma, marginal zone cancer, and diffuse large B-cell lymphoma (DLBCL). An artificially intelligent neural network was trained to uncover novel prognostic indicators for MCL using the expression of gene data. Out of the genes that were linked to low survival, five were linked to excellent survival, and 58 had high-accuracy survival predictions, according to the data.

By identifying *Helicobacter pylori* infection, ocular night scanning plays a crucial role in determining the advancement of cancer of the stomach. In cases of gastrointestinal cancer, colorectal cancer (CRC) screening methods are employed to evaluate the patient's carcinoma stage. For screening and early lung cancer diagnosis, artificial intelligence (AI) is a versatile clinical tool.

Artificial Intelligence Frameworks [Machine Learning Tools]

Robot Pharmacy

To improve patient safety, UCSF Medical Center uses robotic technology to track and manufacture drugs (Figure 4). They state that 3,50,000 doses of medicine have been perfectly manufactured using the technique.

The robot has shown a significant benefit compared to humans regarding its size and precision in dispensing medication [27].



Figure 3. Artificial intelligence in oncology.



Figure 4. Robot pharmacy.

The MEDi Robot

Is an abbreviation that stands for health care and engineering design intelligence. AI tools The University of Calgary's Tanya Beran, an Albertan professor of public health sciences, coordinated the initiative that led to the creation of the pain treatment robot. Working in hospitals where children scream after surgeries gave her the idea. Before telling the kids what to anticipate during a medical procedure, the robot first establishes a rapport with them [28].

TUG Robots

Aethon TUG robots are designed to autonomously navigate hospitals, delivering heavy objects like garbage and linen as well as supplies, food, and prescriptions. It is available in two configurations: permanent and secured carts and an interchange base platform for moving racks, bins, and carts.

Erica Robot

Osaka University professor Hiroshi Ishiguro is the inventor of the brand-new care robot Erica. It was created by the Japan Science and Technology Agency, Kyoto University, and the Advanced Telecommunications Research Institute International (ATR). Its facial features include European and Asian features, and it speaks Japanese. Like any other typical person, it likes to watch animated movies, wants to visit Southeast Asia, and longs for a life companion with whom it can converse [29].

The Following Domains Are Where Artificial Intelligence (AI) Is Used

1. Diagnosis of illness.
2. Digital therapy/individualized care.
3. The use of radiation treatment.
4. The retina.

5. Cancer.
6. Additional long-term conditions.
7. Drug discovery.
8. Bioactivity and toxicity prediction.
9. Investigational studies.
10. Creating clinical trials, finding, attracting, and enrolling people.
11. Trial monitoring, patient compliance, and endpoint identification.
12. Predicting a pandemic or epidemic [30].

ARTIFICIAL INTELLIGENCE'S FUTURE SCOPE

- AI used in science and research.
- AI in cyber security.
- AI in data analysis.
- AI in health care etc.
- AI in the home and in transportation.

AI in both academia and industry. Science has made great strides thanks to AI. Artificial intelligence can manage large volumes of data since its processing speed is faster than that of human brains. It is therefore perfect for research when the sources include substantial volumes of data. AI has already made progress in this field.

AI in Security

Artificial intelligence is also utilized in cybersecurity. As more corporate information is moved to the cloud and IT networks, the threat from hackers is increasing.

Data Analysis Using AI

AI and ML have a substantial effect on data analysis. The accuracy and precision of artificial intelligence systems can be enhanced with every iteration. AI can help data analysts handle extensive datasets.

AI in Transit

The transportation industry has utilized artificial intelligence for a considerable time. Since 1912, aircraft have utilized autopilot systems for navigation during flight. Despite an autopilot system managing the flight path of an aircraft, this technology is not exclusive to the aviation industry. An additional method that assists ships and spacecraft in maintaining their intended path is autopilot [31, 32].

Merits

1. Artificial intelligence can now be employed in the pharmaceutical sector to tackle issues that could not be solved through basic data analysis.
2. Artificial intelligence can do certain tasks more precisely, which reduces expenses and increases output.
3. Clinical study outcomes will be greatly improved by the helpful insights that AI offers.
4. A complete understanding of the interactions between consumer behavior and market dynamics.
5. Businesses can detect problems with substances related to safety and efficacy much quicker because to its assistance in patient selection for clinical studies.
6. Algorithms of artificial intelligence. It encourages the development of new AI algorithms and enhances the efficiency of antiviral detection systems.
7. It also helps the industry's clinical trial patient screening procedure.
8. Artificial intelligence would be less prone to errors than humans if it were built correctly.
9. They would be extraordinarily fast, accurate, and exact.
10. Future robotic surgery will rival human accuracy in performing a variety of surgeries.

11. Deep learning and natural language processing have enabled AI to comprehend and analyze enormous amounts of biological data, revolutionizing the drug discovery process.

De-Merits

1. Because AI cannot think for itself and can simply follow instructions, it typically lacks the human touch.
2. It works well for educating the following generation.
3. Responsive to initial mass damage.
4. If robots start to replace people in every profession, unemployment will ensue.
5. Machines may easily create confusion when utilized poorly, and they can be costly to build, maintain, and restore. Many people fear that, at the very least.
6. Humans become mentally deficient and reliant on AI, as has already been partially shown with smartphones and other technology.
7. AI-powered robots have the capacity to compete with humans and control human beings.

CONCLUSIONS

There has been a discernible rise in interest in the use of AI technology for analysis and interpretation of some important pharmacy fields in recent years, including drug discovery, dosage form designing, polypharmacology, hospital pharmacy, etc. because AI technological approaches believe that humans imagine knowledge, solve problems, and make decisions. AI would benefit everyone by identifying a pharmaceutical core for healthcare research and development, including ANN, CFD, and robotics, given the complex difficulties of today and the promising future. Applying the findings of artificial intelligence might lead to a more accurate description of patients and anticipated results. Because artificial intelligence has made those opportunities appealing, pharmaceutical firms are developing a new generation of computer tools that can tell physicians what will happen within a cell when DNA is changed by genetic variation. We must be able to go forward with every new technological advancement while being aware of and cognizant of its implications. We must embrace this development, utilize AI to help us cope with it, and strive to make society better since, in my opinion, we are living in the age of AI revelation.

REFERENCES

1. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. *Drug Discov Today*. 2019; 24(3):773–780. doi:10.1016/j.drudis.2018.11.014.
2. Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. *Adv Drug Deliv Rev*. 2019;151–152:169–190. doi:10.1016/j.addr.2019.05.001.
3. Russel S, Dewey D, Tegmark M. Research priorities for robust and beneficial artificial intelligence. *AI Mag*. 2015;36(4):105–114. doi:10.1609/aimag.v36i4.2577.
4. Duch W, Setiono R, Zurada JM. Computational intelligence methods for rule-based data understanding. *Proc IEEE*. 2004;92(5):771–805. doi:10.1109/JPROC.2004.826605.
5. Dasta JF. Application of artificial intelligence to pharmacy and medicine. *Hosp Pharm*. 1992;27(4):319–322.
6. Jiang F, Jiang Y, Zhi H. Artificial intelligence in healthcare: past, present and future. *Stroke Vasc Neurol*. 2017;2(4):230–243. doi:10.1136/svn-2017-000101.
7. Gobburu JV, Chen EP. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. *J Pharm Sci*. 1996;85(5):505–510. doi:10.1021/js950433d.
8. Sakiyama Y. The use of machine learning and nonlinear statistical tools for ADME prediction. *Expert Opin Drug Metab Toxicol*. 2009;5(2):149–169. doi:10.1517/17425250902753261.
9. Agatonovic-Kustrin S, Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. *J Pharm Biomed Anal*. 2000;22(5):717–727. doi:10.1016/S0731-7085(99)00272-1.
10. Zhang ZH, Wang Y, Wu WF, Zhao X, Sun XC, Wang HQ. Development of glipizide push-pull osmotic pump controlled release tablets by using expert system and artificial neural network. *Yao Xue Xue Bao*. 2012;47(12):1687–1695

11. Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V. Deep neural nets as a method for quantitative structure–activity relationships. *J Chem Inf Model*. 2015;55(2):263–274. doi:10.1021/ci500747n.
12. Mayr A, Klambauer G, Unterthiner T, Hochreither S. Deep tox: toxicity prediction using deep learning. *Front Environ Sci*. 2016;3:80. doi:10.3389/fenvs.2015.00080.
13. Merk D, Friedrich L, Grisoni F, Schneider G. De novo design of bioactive small molecules by artificial intelligence. *Mol Inform*. 2018;37(1–2):1–4. doi:10.1002/minf.201700153.
14. Bishop CM. Model-based machine learning. *Philos Trans A Math Phys Eng Sci*. 2013;371(1984):20120222. doi:10.1098/rsta.2012.0222.
15. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. *J Health Econ*. 2016;47:20–33. doi:10.1016/j.jhealeco.2016.01.012.
16. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. *Biostatistics*. 2019;20(2):273–286. doi:10.1093/biostatistics/kxx069.
17. Russell SJ, Norvig P, Davis E. Artificial intelligence: A modern approach. London: Prentice Hall; Pearson, 2016.
18. Dill KA, MacCallum JL. The protein-folding problem, 50 years on. *Science*. 2012;338(6110):1042–1046. doi:10.1126/science.1219021.
19. Manikiran SS, Prasanthi NL. Artificial intelligence: Milestones and role in pharma and healthcare sector. *Pharma Times*. 2019;51(1):9–15.
20. Cherkasov A, Hilpert K, Jenssen H, Fjell CD, Waldbrook M, Mullaly SC, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. *ACS Chem Biol*. 2009;4(1):65–74. doi:10.1021/cb800240j.
21. Hintze A. Understanding the four types of AI [Online]. 2022. Available from: <https://theconversation.com/understanding-the-fourtypes-of-ai-from-reactive-robots-to-self-aware-beings-67616>.
22. Silver D, Schrittwieser J, Simonyan K. Mastering the game of go without human knowledge. *Nature*. 2017;550:354–359.
23. Mulholland M. A comparison of classification in artificial intelligence. Induction versus a self-organising neural networks. *Chem Intell Laborat Syst*. 1995;30(1):117–128. doi:10.1016/0169-7439(95)00050-X.
24. Shakya S. Analysis of artificial intelligence-based image classification techniques. *J Innov Image Proc. (JIIP)*. 2020;2(01):44–54. doi:10.36548/jiip.
25. Markoff J. On ‘Jeopardy’ Watson Win is All but Trivial, New York City, The New York Times; 2017. <https://www.nytimes.com/2011/02/17/science/17jeopardy-watson.html>
26. Troulis M, Everett P, Seldin E, Kikinis R, Kaban L. Development of a three-dimensional treatment planning system based on computed tomographic data. *Int J Oral Maxillofacial Surg*. 2002;31(4):349–357. doi:10.1054/ijom.2002.0278.
27. Arimura H, Soufi M, Kamezawa H, Ninomiya K, Yamada M. Radiomics with artificial intelligence for precision medicine in radiation therapy. *J Radiat Res*. 2019;60(1):150–157. doi:10.1093/jrr/rry077.
28. Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunovi H. Artificial intelligence in retina. *Prog Retinal Eye Res*. 2018;67:1–29. doi:10.1016/j.preteyeres.2018.07.004.
29. Feng R, Badgeley M, Mocco J, Oermann EK. Deep learning guided stroke management: a review of clinical applications. *J Neurointerv Surg*. 2018 Apr;10(4):358–362. doi: 10.1136/neurintsurg-2017-013355.
30. Davatzikos C. Machine learning in neuroimaging: Progress and challenges. *Neuroimage*. 2019;197:652–656. doi:10.1016/j.neuroimage.2018.10.003.
31. NagaRavi KT, Suresh KN, Lakshmi GVN, Naseema S, Bhargav SB, Mohiddien SM. Artificial intelligence in pharmacy. *Der Pharmacia Let*. 2021;13(5):6–14.
32. Sharma, Tamanna, et al. Artificial intelligence in advanced pharmacy. *Int J Sci Res Arch*. 2021;2(1):47–54.